Page last updated: 2024-11-12
thioviridamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
thioviridamide: an antineoplastic antibiotic isolated from Streptomyces olivoviridis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Research Excerpts
Overview
Thioviridamide is a ribosomally synthesized and post-translational modified peptide (RiPP) produced by Streptomyces olivoviridis NA005001. It is active against a number of cancer cell lines.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Thioviridamide is a structurally novel ribosomally synthesized and post-translational modified peptide (RiPP) produced by Streptomyces olivoviridis NA005001. " | ( A Genomics-Based Approach Identifies a Thioviridamide-Like Compound with Selective Anticancer Activity. Cappello, AR; Frattaruolo, L; Lacret, R; Truman, AW, 2017) | 2.17 |
| "Thioviridamide is a structurally unique ribosomally synthesized and post-translationally modified peptide that contains several thioamide bonds and is active against a number of cancer cell lines. " | ( Thioholgamides: Thioamide-Containing Cytotoxic RiPP Natural Products. Adam, S; Herrmann, J; Kjaerulff, L; Koehnke, J; Müller, R; Sikandar, A; Zaburannyi, N, 2017) | 1.9 |
| "Thioviridamide is a unique peptide antibiotic containing five thioamide bonds from Streptomyces olivoviridis. " | ( Cloning and heterologous expression of the thioviridamide biosynthesis gene cluster from Streptomyces olivoviridis. Hayakawa, Y; Izawa, M; Kawasaki, T, 2013) | 2.1 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||